SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
50,200
-200 (-0.40%)
At close: Feb 11, 2026
Market Cap3.94T +2.1%
Revenue (ttm)624.03B +210.0%
Net Income-5.90B
EPS-75.30
Shares Out78.43M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume114,207
Average Volume174,934
Open50,700
Previous Close50,400
Day's Range49,950 - 51,200
52-Week Range35,800 - 61,300
Beta1.09
RSI52.39
Earnings DateFeb 3, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 917
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

Financial Statements